StreetInsider.com News Articles

Form EFFECT Nexalin Technology, Inc.

Fri, 16 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261016/27195280.html

Form S-1/A Nexalin Technology, Inc.

Thu, 08 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261008/27167628.html

Nexalin Technology regains Nasdaq bid price compliance

Thu, 08 Oct 2026 08:30:27 -0400

Nexalin Technology, Inc. (NASDAQ: NXL) announced it has received written confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Nasdaq confirmed that the closing bid price of the company's common stock remained above the $1.00 per share minimum for 21 consecutive trading days, from August 31 through September 29, 2026, following a previously announced reverse stock split. The confirmation is dated September 30, 2026.

The confirmation follows a September 25, 2026, decision by the Nasdaq Hearings Panel granting the company's request for continued listing. Under the terms of that decision, Nexalin must

Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing

Thu, 08 Oct 2026 08:30:00 -0400

Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs

HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received written confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq confirmed that the closing bid price of the Company’s common stock was above the $1.00 per share minimum for

Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing

Thu, 08 Oct 2026 08:30:00 -0400

Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs

Form 8-K Nexalin Technology, Inc. For: Sep 30

Thu, 01 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27136990.html

Form 8-K Nexalin Technology, Inc. For: Sep 28

Thu, 01 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27136985.html

Nexalin Technology Inc. (NXL) PT Lowered to $15 at Maxim Group

Thu, 01 Oct 2026 14:18:03 -0400

Maxim Group analyst Anthony Vendetti lowered the price target on Nexalin Technology Inc. (NASDAQ: NXL) to $15.00 while maintaining a Buy rating.

These Stocks Roar into October with Fresh Catalysts

Thu, 01 Oct 2026 12:39:12 -0400

DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The markets are charging into October with a wave of fresh milestones and potential catalysts, putting Nexalin Technology (NASDAQ:NXL), Kraig Biocraft Laboratories (OTCQB:KBLB), Veea (NASDAQ:VEEA), and DataMeds AI (NASDAQ:MEDS) firmly in the market spotlight.